ClinicalTrials.gg
Not yet recruitingNCT07408908Updated Feb 13, 2026

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

A Phase 1 interventional study of ACT100 Injection and Placebo for ACT100 in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a Phase Ia, single-center, randomized, double-blind, dose-escalation, placebo-controlled clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profile of ACT100 in healthy participants. A total of 6 dose cohorts are planned, with each cohort enrolling 8 participants (including both male and female participants, where 6 will receive the investigational drug and 2 will receive placebo). The total planned enrollment is 48 healthy participants.

02

Conditions studied

  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus
  • ACT100
  • Pharmacokinetics and Pharmacodynamics
03

In context

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's planned enrollment of 48 is close to the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 33 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must voluntarily participate and sign the form after being informed of the entire trial process and the potential adverse reactions of the product.
  2. Healthy male and female participants aged between 18 and 55 years (inclusive) at the time of signing the informed consent form.
  3. (BMI) at screening: 18.5 kg/m\^2 ≤ BMI \< 28 kg/m\^2; body weight ≥ 50 kg (for males) / ≥ 45 kg (for females).
  4. At screening, physical examination, vital signs, laboratory tests, (ECG), etc., are all normal or show abnormalities judged by the investigator as having no clinical significance.
  5. Females of and males must agree to use highly effective methods (e.g., intrauterine device, condom) from screening until 3 months after administration of the investigational product and have no plan for sperm or egg donation.

Exclusion criteria

Exclusion Criteria:

  1. History of treatment with any drug targeting the same molecule (BDCA2) as the product.
  2. A 12-lead (ECG) at screening showing abnormalities considered by the investigator (e.g., > 450 ms for males or > 470 ms for females).
  3. History of severe diseases of major organ systems, including but not limited to neurological, cardiovascular, hematological, , renal, hepatic, gastrointestinal, pulmonary, endocrine, metabolic, or psychiatric disorders.
  4. Presence of severe bacterial or viral infection (e.g., pneumonia, sepsis, herpes zoster), or fungal/parasitic infection within 2 months prior to screening; or any symptoms of active or suspected infection within 1 week prior to dosing.
  5. Chronic infectious diseases such as chronic or C, AIDS, tuberculosis, etc. Exclusion applies if any of the following tests are positive at screening: Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), antibody (HCVAb), Treponema pallidum antibody, antibody (HIVAb); or if there is evidence of active or latent Mycobacterium tuberculosis infection at screening.
  6. History of primary immunodeficiency, splenectomy, or any other underlying condition deemed by the investigator to confer a high risk of severe infection.
  7. History of severe food or drug allergy, or known allergy to monoclonal antibodies.
  8. Vaccination with a within 1 month prior to screening, or any other vaccination within half a month prior to screening, or plans to receive any vaccine during the study period.
  9. Use of any prescription drugs, over-the-counter medications (including Chinese herbal medicines, health supplements, etc.) within 14 days prior to the first dose of the investigational product, unless deemed by both the investigator and sponsor to have no impact on the study.
  10. History of drug abuse, illicit drug use, or alcohol abuse (history of drug abuse or illicit drug use within the past 5 years; or habitual alcohol intake exceeding 14 units per week within 3 months prior to screening: 1 unit ≈ 285 mL beer, or 25 mL spirits, or 100 mL wine). Participants with a positive alcohol breath test or positive urine drug abuse screening at screening will be excluded.
  11. Heavy smoking (averaging >5 cigarettes per day) within 3 months prior to screening, or unwillingness to refrain from smoking during the study period.
  12. Donation or loss of >400 mL of blood within 3 months prior to screening, or >200 mL within 1 month prior to screening; or receipt of blood transfusion or blood products within 3 months prior to screening.
  13. Participation in another clinical trial involving an investigational drug/therapy within 1 month prior to screening, or within 5 half-lives (based on the known half-life of the prior investigational product, the Investigator's Brochure, or the form, whichever specifies the longer period).
  14. History of blood/needle phobia or intolerance to venipuncture, or abnormalities at the potential injection site deemed by the investigator to be unsuitable for subcutaneous administration.
  15. Females who are pregnant or lactating.
  16. Any other condition that, in the judgment of the investigator, makes the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    ACT100 Cohort 1

    Drug: ACT100 Injection

  • Placebo comparator
    Placebo Group for Cohort 1

    Drug: Placebo for ACT100

  • Experimental
    ACT100 Cohort 2

    Drug: ACT100 Injection

  • Placebo comparator
    Placebo Group for Cohort 2

    Drug: Placebo for ACT100

  • Experimental
    ACT100 Cohort 3

    Drug: ACT100 Injection

  • Placebo comparator
    Placebo Group for Cohort 3

    Drug: Placebo for ACT100

  • Experimental
    ACT100 Cohort 4

    Drug: ACT100 Injection

  • Placebo comparator
    Placebo Group for Cohort 4

    Drug: Placebo for ACT100

  • Experimental
    ACT100 Cohort 5

    Drug: ACT100 Injection

  • Placebo comparator
    Placebo Group for Cohort 5

    Drug: Placebo for ACT100

  • Experimental
    ACT100 Cohort 6

    Drug: ACT100 Injection

  • Placebo comparator
    Placebo Group for Cohort 6

    Drug: Placebo for ACT100

Interventions

  • DrugACT100 Injection

    a single 5-mg subcutaneous injection

  • DrugPlacebo for ACT100

    a single 5-mg subcutaneous injection

  • DrugACT100 Injection

    a single 25-mg subcutaneous injection

  • DrugPlacebo for ACT100

    a single 25-mg subcutaneous injection

  • DrugACT100 Injection

    a single 100-mg subcutaneous injection

  • DrugPlacebo for ACT100

    a single 100-mg subcutaneous injection

  • DrugACT100 Injection

    a single 300-mg subcutaneous injection

  • DrugPlacebo for ACT100

    a single 300-mg subcutaneous injection

  • DrugACT100 Injection

    a single 600-mg subcutaneous injection

  • DrugPlacebo for ACT100

    a single 600-mg subcutaneous injection

  • DrugACT100 Injection

    a single 800-mg subcutaneous injection

  • DrugPlacebo for ACT100

    a single 800-mg subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Adverse Event(AE)

    Time frame: Day 1-84

  2. Serious Adverse Event

    Time frame: Day 1-84

  3. blood pressure

    Time frame: Day 1-84

  4. pulse

    Time frame: Day 1-84

  5. respiration

    Time frame: Day 1-84

  6. body temperature

    Time frame: Day 1-84

  7. Number of Participants with Abnormal Physical examination parameters

    Time frame: Day 1-84

  8. Number of Participants with Abnormal Laboratory Parameters Findings

    Time frame: Day 1-84

  9. Number of Participants with 12-Lead Electrocardiogram Findings

    Time frame: Day 1-84

Secondary outcomes

  1. Area Under the plasma concentration-time Curve from time zero to the last measurable concentration(AUC₀-t)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  2. Area Under the plasma concentration-time Curve from time zero extrapolated to infinity(AUC₀-∞)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  3. Maximum observed plasma concentration(Cmax)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  4. Time to reach the maximum observed plasma concentration(Tmax)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  5. Terminal elimination half-life(t1/2)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  6. Apparent clearance (CL/F)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  7. Apparent volume of distribution(Vd/F)

    Time frame: Day 1-4,7,14,21,28,42,56,70,84

  8. Levels of BDCA2 on the surface of plasmacytoid dendritic cells (pDCs)

    Time frame: Day 1-3,7,14,28,42,56,70,84

  9. Peripheral blood pDC levels

    Time frame: Day 1-3,7,14,28,42,56,70,84

  10. Anti-drug antibodies (ADA).

    Time frame: Day 1,28,56,84

  11. Neutralizing antibodies (NAb)

    Time frame: Day 1,28,56,84

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 12 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartEst.
Mar 6, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07408908
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Mar 6, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Xiaohong Han
Contact
hanxiaohong@pumch.cn
050-69154796
Xiaohong Han
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion